Q4-FY26 · AJ (A.J. Kumar Mahanti)
This financial year 26 was a landmark year in the journey. A successful commissioning and capitalization of our largest manufacturing facility in Baddi marks a major milestone for the company.
QLINEBIOTECH / language trends
Read confidence between the lines.
Qlinebiotech · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Minal Gupta
EBITDA increased by 39% to Rs 98.1 crores compared to Rs 70.6 crores in FY25. The EBITDA margin improved from 22.5% to 28.7% reflecting the benefits of a manufacturing-led strategy.
Q4-FY26 · Minal Gupta
It takes approximately Rs 25,000 of average reagents per machine per month which is about Rs 3 lakhs through the economic life of about 10 years means it's almost about Rs 30 lakhs per analyzer revenue potential.
Q4-FY26 · VS Prabhakaran
We are expecting more than 5x in coming year 2027 but the CDMO business will be totally additional business... it will be around Rs 1 million so around Rs 10 crores.